For research use only. Not for therapeutic Use.
TRAM-34（Cat No.:I003001） is a potent and selective intermediate conductance Ca2+-activatedK+channel (IKCa1, KCa3.1) Chemicalbook (calcium-activated K+ channel) inhibitor with Kd of 20nM, which is more selective than other ion channels 200 to 1500-fold without inhibition of cytochrome P450.
| Catalog Number | I003001 |
| CAS Number | 289905-88-0 |
| Synonyms | 1-[(2-chlorophenyl)-diphenylmethyl]pyrazole |
| Molecular Formula | C22H17ClN2 |
| Purity | ≥95% |
| Target | Potassium Channel |
| Solubility | DMSO: ≥ 3.4 mg/mL |
| Storage | 2-8°C |
| IC50 | 20 nM (Kd) |
| IUPAC Name | 1-[(2-chlorophenyl)-diphenylmethyl]pyrazole |
| InChI | InChI=1S/C22H17ClN2/c23-21-15-8-7-14-20(21)22(25-17-9-16-24-25,18-10-3-1-4-11-18)19-12-5-2-6-13-19/h1-17H |
| InChIKey | KBFUQFVFYYBHBT-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CC=N4 |
| Reference | </br>1:[Effects of TRAM-34 on Proliferation and Invasion of Leukemia Cell Line HL-60]. Jiang TH, Huang ZG.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):104-109. doi: 10.7534/j.issn.1009-2137.2017.01.018. Chinese. PMID: 28245384 </br>2:Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells. Bauer D, Werth F, Nguyen HA, Kiecker F, Eberle J.Cell Death Dis. 2017 Feb 2;8(2):e2594. doi: 10.1038/cddis.2017.6. PMID: 28151482 Free PMC Article</br>3:K<sub>Ca</sub>3.1 (IK) modulates pancreatic cancer cell migration, invasion and proliferation: anomalous effects on TRAM-34. Bonito B, Sauter DR, Schwab A, Djamgoz MB, Novak I.Pflugers Arch. 2016 Nov;468(11-12):1865-1875. Epub 2016 Oct 17. PMID: 27752766 </br>4:Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Glaser N, Little C, Lo W, Cohen M, Tancredi D, Wulff H, O/’Donnell M.Pediatr Diabetes. 2016 May 13. doi: 10.1111/pedi.12396. [Epub ahead of print] PMID: 27174668 </br>5:TRAM-34 attenuates hypoxia induced pulmonary artery smooth muscle cell proliferation. Guo SJ, Wang T, Jia LQ, Li DD, Shen YC, Xu D, Wen FQ.Eur Rev Med Pharmacol Sci. 2015 Sep;19(18):3515-21. PMID: 26439051 Free Article</br>6:Using Visualized Matrix Effects to Develop and Improve LC-MS/MS Bioanalytical Methods, Taking TRAM-34 as an Example. Ye JH, Pao LH.PLoS One. 2015 Apr 24;10(4):e0118818. doi: 10.1371/journal.pone.0118818. eCollection 2015. PMID: 25909956 Free PMC Article</br>7:Ca2+ -activated K+ channel-3.1 blocker TRAM-34 alleviates murine allergic rhinitis. Lin H, Zheng C, Li J, Yang C, Hu L.Int Immunopharmacol. 2014 Dec;23(2):642-8. PMID: 25466273 </br>8:Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models. Ongerth T, Russmann V, Fischborn S, Boes K, Siegl C, Potschka H.Eur J Pharmacol. 2014 Oct 5;740:72-80. doi: 10.1016/j.ejphar.2014.06.061. Epub 2014 Jul 10. PMID: 25016931 </br>9:Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34. Freise C, Querfeld U.Pharmacol Res. 2014 Jul;85:6-14. doi: 10.1016/j.phrs.2014.04.013. Epub 2014 May 6. PMID: 24813858 </br>10:TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. Agarwal JJ, Zhu Y, Zhang QY, Mongin AA, Hough LB.PLoS One. 2013 May 7;8(5):e63028. doi: 10.1371/journal.pone.0063028. Print 2013. PMID: 23667566 Free PMC Article |
